Target
GNAQ
15 products, 15 indications
Indications
BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma (8 products)
BRAF-mutant melanoma (4 products)
metastatic melanoma (2 products)
Advanced melanoma (2 products)
BRAF V600E mutation-positive metastatic NSCLC (1 products)
metastatic non-small cell lung cancer (1 products)
Stage III melanoma (1 products)
BRAF-mutant NSCLC (1 products)
Erdheim-Chester Disease (1 products)
Unresectable metastatic melanoma (1 products)
Uveal melanoma (1 products)
clinical stages IIIB-IIID melanoma (1 products)
BRAF-mutated, unresectable locally advanced stage III or oligometastatic stage IV melanoma (1 products)
resected high-risk stage III/IV cutaneous melanoma (1 products)
Resected stage III/IV BRAF V600-mutated melanoma (1 products)
Loading...
1 drug
4 abstracts
Abstract
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).Org: Immunocore Ltd., Immunocore LLC,
Abstract
Real world experience of molecular landscape of uveal melanomas: Implications for personalized medicine strategies.Org: Leaders in Oncology Care, HCA Healthcare UK,
Abstract
NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).Org: Royal Victorian Eye and Ear Hospital, Melbourne, Australia, University of Sydney, Sydney, Australia, Princess Alexandra Hospital, Greenslopes Private Hospital and University of Queensland, Brisbane, Australia, Queensland Institute of Medical Research Berghofer, Herston, Australia, Terrace Eye Centre, Brisbane, Australia,
Abstract
Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.Org: Yemaachi Biotech, Cape Coast Teaching Hospital, University of Cape Coast, Lucence Diagnostics Pte Ltd, Lucence Health Inc,
Drug
Vemurafenib